BREAST DUCTAL CARCINOMA IN SITU
Clinical trials for BREAST DUCTAL CARCINOMA IN SITU explained in plain language.
Never miss a new study
Get alerted when new BREAST DUCTAL CARCINOMA IN SITU trials appear
Sign up with your email to follow new studies for BREAST DUCTAL CARCINOMA IN SITU, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for chemo-resistant breast cancer? trial tests targeted pill
Disease control TerminatedThis study tested a drug called abemaciclib in people with triple negative breast cancer that did not shrink with standard chemotherapy. The goal was to see if the drug could change the immune environment inside the tumor, making it more responsive. The trial was stopped early, b…
Matched conditions: BREAST DUCTAL CARCINOMA IN SITU
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
Hot flash drug studied for breast cancer survivors, but trial cut short
Symptom relief TerminatedThis study tested fezolinetant, a drug that blocks a brain receptor involved in temperature control, to see if it could reduce hot flashes and night sweats in women with breast cancer taking hormone-lowering medications. The trial planned to enroll many participants but was stopp…
Matched conditions: BREAST DUCTAL CARCINOMA IN SITU
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated May 12, 2026 13:43 UTC